Fate Therapeutics (FATE) Operating Leases (2019 - 2026)
Fate Therapeutics' (FATE) quarterly Operating Leases came in at $72.0 million in Q1 2026, down 6.17% YoY from $76.8 million in Q1 2025, and down 1.69% on a QoQ basis from $73.3 million in Q4 2025.
Fate Therapeutics (FATE) Operating Leases (2019 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 8 years of Operating Leases data on file, last reported at $72.0 million in Q1 2026.
- Quarterly Operating Leases fell 6.17% year-over-year to $72.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.0 million (down 6.17% YoY) and the FY2025 annual result came in at $73.3 million, down 5.86% from the prior year.
- Operating Leases eased to $72.0 million in Q1 2026, from $73.3 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $107.9 million in Q1 2022 to a low of $72.0 million in Q1 2026.
- A 5-year average of $91.4 million and a median of $95.7 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases climbed 1.34% — and 2024, when it dropped 20.04%.
- Tracing FATE's Operating Leases over 5 years: stood at $103.7 million in 2022, then decreased by 6.12% to $97.4 million in 2023, then retreated by 20.04% to $77.8 million in 2024, then decreased by 5.86% to $73.3 million in 2025, then fell by 1.69% to $72.0 million in 2026.
- The last three Operating Leases figures came in at $72.0 million (Q1 2026), $73.3 million (Q4 2025), and $74.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72.05 Mn |
| Dec 31, 2025 | 73.29 Mn |
| Sep 30, 2025 | 74.49 Mn |
| Jun 30, 2025 | 75.68 Mn |
| Mar 31, 2025 | 76.79 Mn |
| Dec 31, 2024 | 77.85 Mn |
| Sep 30, 2024 | 92.09 Mn |
| Jun 30, 2024 | 93.92 Mn |
| Mar 31, 2024 | 95.67 Mn |
| Dec 31, 2023 | 97.36 Mn |
| Sep 30, 2023 | 98.98 Mn |
| Jun 30, 2023 | 100.56 Mn |
| Mar 31, 2023 | 102.07 Mn |
| Dec 31, 2022 | 103.71 Mn |
| Sep 30, 2022 | 105.16 Mn |
| Jun 30, 2022 | 106.59 Mn |
| Mar 31, 2022 | 107.94 Mn |
| Dec 31, 2021 | 109.24 Mn |
| Sep 30, 2021 | 104.36 Mn |
| Jun 30, 2021 | 105.41 Mn |